Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aim: To report the experience with vildagliptin in a patient population with type 2 diabetes mellitus (T2DM) ≥75 years. Methods: Efficacy data from seven monotherapy and three add‐on therapy to metformin studies, respectively, of ≥24 weeks duration were pooled; effects of 24 weeks of treatment with vildagliptin (50 mg bid) in patients ≥75 years were assessed in these two pooled datasets. Safety data were pooled from 38 studies of ≥12 to ≥104 weeks duration; adverse events (AEs) profiles of vildagliptin (50 mg bid) were evaluated relative to a pool of comparators; 301 patients ≥75 years were analysed. Data in patients <75 years are provided as a reference. Results: Mean age of the elderly population was 77 years. Changes in haemoglobin A1c (HbA1c) with vildagliptin in the patient group ≥75 years were −0.9% from a baseline of 8.3% in monotherapy (p < 0.0001) and −1.1% from a baseline of 8.5% in add‐on therapy to metformin (p = 0.0004), and these reductions were similar to those seen in the younger patients. The corresponding weight changes in the elderly patients were −0.9 kg (p = 0.0277) and −0.2 kg [not significant (NS)], respectively, and no confirmed hypoglycaemic events, including no severe events, were reported. AEs, drug‐related AEs, serious adverse events (SAEs) and deaths were reported with a lower frequency in older patients receiving vildagliptin than comparators [133.9 vs. 200.6, 14.5 vs. 21.8, 8.8 vs. 16.5 and 0.0 vs. 1.7 events per 100 subject year exposure (SYE), respectively], and the incidence of discontinuations due to AEs was similar in the two groups (7.2 vs. 7.5 events per 100 SYE, respectively). The safety profile of vildagliptin was overall similar in younger and older patients. Conclusions: Vildagliptin was effective and well‐tolerated in type 2 diabetic patients ≥75 years (mean age 77 years).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Chang, A. M., & Halter, J. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00366.2002 · Cited by 585
Leite, N. C., Salles, G. F., Araujo, A. L. E., Villela‐Nogueira, C. A., & Cardoso, C. R. L. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01718.x · Cited by 531
Mechanisms of the Age-Associated Deterioration in Glucose Tolerance
Basu, R., Breda, E., Oberg, A. L., Powell, C. C., Dalla Man, C., Basu, A., Vittone, J. L., Klee, G. G., Arora, P., Jensen, M. D., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1738 · Cited by 440 · cited 1×
“T2DM in older individuals is known to be associated with relative hyperglucagonaemia [46] and elevated postprandial glucose [47].”
BackgroundAssociation of Hypoglycemia and Cardiac Ischemia
Desouza, C., Salazar, H., Cheong, B., Murgo, J., & Fonseca, V. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1485 · Cited by 406
Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes
Bremer, J. P., Jauch-Chara, K., Hallschmid, M., Schmid, S., & Schultes, B. (2009) · Diabetes Care · doi:10.2337/dc09-0114 · Cited by 298
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diab.43.3.403 · Cited by 167 · cited 1×
“The risk of hypoglycaemia associated with the use of oral antidiabetic agents or insulin increases markedly with age [10] and the risk of adverse consequences is further”
BackgroundCounterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diabetes.43.3.403 · Cited by 167
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“Although vildagliptin has demonstrated efficacy and safety in patients ≥ 75 years [262] , data safety in these patients is very limited.”
BackgroundEfficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2868 · Cited by 87
Batule, S., Ramos, A., Pérez-Montes de Oca, A., Fuentes, N., Martínez, S., Raga, J., Pena, X., Tural, C., Muñoz, P., Soldevila, B., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102813 · Cited by 13
“Among this group of antidiabetic oral agents, there is currently only one safety study in subjects older than 75 years, performed with vildagliptin to support its use in elderly patients [10].”
Background
Metadata
- Authors
- Schweizer, A., Dejager, S., Foley, J. E., Shao, Q., & Kothny, W.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2010-11-28
- Volume
- 13
- Issue
- 1
- Pages
- 55-64
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2129064931
- Cited by
- 103
- References
- 8
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01325.x
- The paper
- Schweizer, A., Dejager, S., Foley, J. E., Shao, Q., & Kothny, W. (2011). Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01325.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.